Physician profile
Devon Ashley Joyce
NPI 1467049395
$1,303.42
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $611 · 2023: $661 · 2024: $31.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $693.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $692.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $413.31 | 2022-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $174.30 | 2022 | |
| Lilly USA, LLC | $130.76 | 2022-2023 | Mounjaro, Jardiance, Emgality |
| Alkermes, INC. | $77.50 | 2022-2023 | Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $74.22 | 2022-2023 | |
| Novo Nordisk INC | $66.44 | 2023 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $54.15 | 2022-2023 | Bexsero |
| Takeda Pharmaceuticals U.S.A., INC. | $46.98 | 2022-2023 | Trintellix |
| Exact Sciences Corporation | $46.74 | 2023 | Cologuard Collection Kit |
| Seqirus USA INC | $43.29 | 2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Axsome Therapeutics, INC. | $31.38 | 2023 | Sunosi |
| Pfizer INC. | $29.21 | 2023 | |
| Vanda Pharmaceuticals INC. | $27.58 | 2022 | |
| Lundbeck LLC | $24.23 | 2023 | Rexulti |
| Exeltis, USA INC. | $23.84 | 2023 | Slynd |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $23.31 | 2023 | |
| Ironshore Pharmaceuticals INC. | $16.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devon Joyce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.